Kevin Lobo Acquires 10,000 Shares of GE HealthCare Technologies (NASDAQ:GEHC) Stock

GE HealthCare Technologies Inc. (NASDAQ:GEHC) Director Kevin Lobo acquired 10,000 shares of GE HealthCare Technologies stock in a transaction dated Friday, May 22nd. The shares were acquired at an average price of $64.18 per share, with a total value of $641,800.00. Following the transaction, the director owned 14,363 shares in the company, valued at approximately $921,817.34. This represents a 229.20% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC traded down $0.05 during midday trading on Tuesday, reaching $64.18. The company’s stock had a trading volume of 4,011,279 shares, compared to its average volume of 4,231,655. GE HealthCare Technologies Inc. has a one year low of $58.75 and a one year high of $89.77. The company has a market cap of $29.19 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 1.45 and a beta of 0.74. The company has a 50 day moving average price of $68.33 and a 200 day moving average price of $76.18. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). The business had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, equities research analysts expect that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

Institutional Trading of GE HealthCare Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of GE HealthCare Technologies by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock valued at $4,287,658,000 after buying an additional 267,058 shares in the last quarter. Auto Owners Insurance Co lifted its stake in GE HealthCare Technologies by 9,525.4% in the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after acquiring an additional 33,629,559 shares in the last quarter. Dodge & Cox lifted its stake in GE HealthCare Technologies by 13.4% in the 4th quarter. Dodge & Cox now owns 31,211,229 shares of the company’s stock worth $2,559,945,000 after acquiring an additional 3,693,918 shares in the last quarter. Capital Research Global Investors boosted its position in GE HealthCare Technologies by 1.6% during the 4th quarter. Capital Research Global Investors now owns 25,362,352 shares of the company’s stock worth $2,080,248,000 after acquiring an additional 389,796 shares during the period. Finally, State Street Corp boosted its position in GE HealthCare Technologies by 2.0% during the 4th quarter. State Street Corp now owns 20,049,677 shares of the company’s stock worth $1,644,475,000 after acquiring an additional 401,932 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GEHC shares. Jefferies Financial Group cut their target price on GE HealthCare Technologies from $105.00 to $90.00 in a research report on Thursday, April 30th. UBS Group upgraded GE HealthCare Technologies from a “sell” rating to a “neutral” rating and decreased their price target for the company from $75.00 to $69.00 in a research report on Thursday, May 21st. Argus dropped their price target on GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen downgraded GE HealthCare Technologies from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and a consensus target price of $80.21.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.